TrialPath

171 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

126 studies on the map

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma — Allervie Clinical Research, BirminghamStudy of ALTO-300 in MDD — Site 200, PhoenixA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonA Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma — Kymera Investigative Site, LancasterA Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma — AMR Clinical, TempeDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids — Research Site, BakersfieldA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Velocity Clinical Research, Mobile, MobileA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma — Research Site, BakersfieldZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults — Enveda Investigative Site, BirminghamA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia — Precision Clinical Research, SunriseCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookA Study of CDX-622 in Participants With Mild to Moderate Asthma — University of California, San Francisco, San FranciscoModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimoreUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoSoy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study — Ann and Robert H Lurie Childrens Hospital of Chicago, ChicagoPhase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma — Sun City Clinical Research, GlendaleA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CitySearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoSupplementing L-citrulline to Overweight Late Asthma oNset Phenotypes — Duke University (Asthma, Allergy and Airway Center), DurhamStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisLiver Adiposity Effects on Pediatric Statin — Children's Mercy Hospital, Kansas CityEvaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity — University of Connecticut, StorrsAnti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma — University of Colorado Anschutz Medical Campus, AuroraA Clinical Trial of Soluble Fiber for Asthma — Phoenix Children's, PhoenixKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma — Pfizer Clinical Research Unit - New Haven, New HavenStudy to Improve Deployment Related Asthma by Using L-Citrulline Supplementation — National Jewish Health, DenverEscitalopram in Asthma Patients With Frequent Exacerbation — UT Southwestern, 1440 Empire Central, Ste. LD4.100, DallasTimely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation — Oklahoma Children's Hospital, Oklahoma CityOmalizumab Before Onset of Exacerbations — Children's National Hospital, Washington D.C.A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study — Kymera Investigative Site, TampaPilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation — Massachusetts General Hospital, BostonViral Mucosal Reprogramming — University of Texas Medical Branch, GalvestonAzithromycin for Critical Asthma - Pediatrics — Johns Hopkins All Children's Hospital, St. PetersburgReslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study — National Jewish Health, Denver5HTP Regulation Of Asthma In Children — Indiana University, IndianapolisVENTURI (VENTilation Using Respiratory Imaging) — The University of Alabama at Birmingham, BirminghamKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisApimostinel + Automated Neurocognitive Training for Depression — Western Psychiatric Institute and Clinic, PittsburghImaging Depression in Parkinson's Disease — Yale University, New HavenSynaptic Mechanisms of Continuous Theta Burst Stimulation in Depression — McLean Hospital, BelmontAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease — Johns Hopkins Center for Psychedelic and Consciousness Research, BaltimoreA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression — UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los AngelesPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los AngelesEfficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder — McLean Hospital, BelmontDBS for Depression — Zucker Hillside Hospital, QueensDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GrovePsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder — Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New YorkProbiotic Administration for Adolescent Depression — UCSF, San FranciscoNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaLeucine in Midlife Depression — Emory University Hospital, AtlantaPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaJAK Signaling in Depression — Emory University, AtlantaModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonClemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression — University of Illinois College of Medicine, ChicagoKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New York[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaSleep to Reduce Incident Depression Effectively in Peripartum — Henry Ford Medical Center, NoviStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsSodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) — NYU Langone Health, New YorkRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesMindfulness Engaged Neurostimulation for Depression (MEND II) — UC San Diego Health Psychiatry, San DiegoCannabidiol for Reduction of Brain Neuroinflammation — Massachusetts General Hospital, BostonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkOrexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial — James J. Peters Veterans Affairs Medical Center, The BronxPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, ColumbusPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattlePsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesNeurobiology of Suicide — National Institutes of Health Clinical Center, BethesdaEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenConfirmatory Efficacy Trial of Attention Bias Modification for Depression — Institute for Mental Health Research, Austin

Showing the 150 nearest — narrow your filters for fewer, closer studies.